Ocular and nasal symptoms prior to acute skin graft‐versus‐host disease
Ikuko Fujihara,R. Yanagisawa,Ririko Sato,Noritaka Kitazawa,K. Sakashita
DOI: https://doi.org/10.1111/ped.13280
2017-05-15
Pediatrics International
Abstract:A 5-year-old boy was diagnosed with stage IV neuroblastoma. The primary lesion was the left adrenal gland with general metastasis to the bone and bone marrow. He received allogeneic bone marrow transplantation (BMT) from his HLA 2-loci mismatched father for residual neuroblastoma after treatment, including systemic chemotherapy and autologous peripheral blood stem cell transplantation (SCT), without any local treatment. The preparative regimen for BMT consisted of 12 Gy total body irradiation and cyclophosphamide at 120 mg/kg. Prophylaxis against graft-versus-host disease (GVHD) included tacrolimus and short-term methotrexate. His status after BMT was stable, and there was no regimen-related toxicity including mucositis. Engraftment was achieved on day 16 after BMT, but numerous symptoms were observed on day 26 after BMT, including fever (temperature, 38.1°C), swelling of the eyelid, ocular pruritus, conjunctival hyperemia, nasal discharge, and nasal obstruction (Fig. 1a,b). These symptoms were similar to those of infection, such as adenovirus and enterovirus infection, or allergic disease, but he had been isolated and treated in a sterile room during the period of BMT, and qualitative polymerase chain reaction (PCR) of peripheral blood was negative for Epstein–Barr virus, cytomegalovirus (CMV), human herpesviruses 6 and 7, and Herpes simplex viruses 1 and 2 (HSV-1/2). Qualitative PCR and antigen detection of conjunctival swabs were negative for HSV-1/2, Varicella zoster virus, CMV, and adenovirus. There were no findings of conjunctival follicle indicative of viral infection or allergic conjunctivitis. On day 28 after BMT, he developed a skin rash covering >60% of his body. Additionally, the rash appeared on the eyelid and around the nose (Fig. 1c). The previously observed ocular and nasal symptoms worsened after the appearance of the acute skin rash, and further symptoms of photophobia and ocular pain appeared. Although we could not perform biopsy because of the need for urgent treatment at night and issues with correspondence in the pediatric care unit at night, acute grade II GVHD was diagnosed according to the acute GVHD diagnosis and management guidelines. Differential diagnoses, including drug reaction, viral exanthem, engraftment syndrome, and effects of chemotherapy or radiation, were negative. There were no other symptoms of GVHD in the liver or gut. Treatment with systemic i.v. prednisolone at 1 mg/kg/ day and topical steroids to the eyes was initiated immediately, in addition to continuous drip infusion of tacrolimus (blood concentration during this period, 10.6–15.2 ng/mL). The next morning, most of the skin rash had improved. On day 35 after BMT, however, a large, round corneal epithelial erosion with no opacity was noted on fluorescein staining (Fig. 1d). The abrasion indicated depression of limbal function. Although systemic i.v. prednisolone was increased to 2 mg/kg/day, the patient could not open his eyes for 4 weeks because of severe pain. He needed to be placed in a darkened room even during the daytime because of light aversion. Head magnetic resonance imaging at this time showed bilateral sinusitis without evidence of infection (Fig. S1). All of the symptoms improved within 5 weeks after initiation of systemic i.v. prednisolone. Ocular GVHD is a well known symptom of chronic phase GVHD. The most frequent manifestation is dry eye syndrome (keratoconjunctivitis sicca). Onset in the acute phase, however, is rare and usually occurs in the context of other systemic GVHD because the cornea and conjunctiva are immunological targets, with histology similar to that seen in cutaneous GVHD. Ocular involvement is considered to be a poor prognostic factor for mortality due to systemic acute GVHD. Although some reports have indicated that post-SCT sinusitis is related to acute GVHD, few reports on nasal GVHD are available. In the present case, it was difficult to identify ocular GVHD as a symptom of acute GVHD with ocular and nasal symptoms because this condition appeared prior to the typical acute skin GVHD and resembled a common infection or allergic disease. Ocular GVHD can become severe and cause distress. Early recognition and careful monitoring might prevent permanent tissue damage. Ocular and nasal symptoms that resemble those of a common infection or allergic disease after allogeneic SCT may need attention as atypical indications of acute GVHD. Correspondence: Ryu Yanagisawa, MD, PhD, Division of Blood Transfusion, Shinshu University Hospital, 3-1-1 Asahi, Matsumoto 390-8621, Japan. Email: ryu@shinshu-u.ac.jp Received 31 December 2016; revised 28 February 2017; accepted 7 March 2017. doi: 10.1111/ped.13280